Unnamed: 0,title,date,stock,sentiment
19272.0,"The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset",2020-06-10 07:30:00-04:00,ACRX,positive
19273.0,"The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic",2020-06-04 08:13:00-04:00,ACRX,positive
19274.0,Acelrx Pharmaceuticals  Will Be Paid a Break-up Fee of ~$1.8M,2020-06-03 18:52:00-04:00,ACRX,neutral
19275.0,AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetraphase,2020-06-03 18:51:00-04:00,ACRX,neutral
19276.0,"The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs",2020-06-02 07:45:00-04:00,ACRX,negative
19277.0,20 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-06-02 07:32:00-04:00,ACRX,neutral
19278.0,"UPDATE: Under Amended Melinta Proposal, Melinta Has Offered To Acquire Tetraphase For $39M In Cash Plus $16M In Cash Potentially Payable Under Contingent Value Rights",2020-06-01 16:55:00-04:00,ACRX,positive
19279.0,"UPDATE: Tetraphase Announces $37M Valuation, $18.7M In Stock Warrants, In Merger With AcelRx",2020-05-29 08:51:00-04:00,ACRX,neutral
19280.0,AcelRx Pharmaceuticals Announces Revised Merger Agreement With Tetraphase,2020-05-29 08:35:00-04:00,ACRX,positive
19281.0,"The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened Offer",2020-05-28 08:24:00-04:00,ACRX,neutral
19282.0,"Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx",2020-05-27 20:58:00-04:00,ACRX,positive
19283.0,"UPDATE: Tetraphase Shareholders Will Receive For Each Share $0.2434/Share In Cash, 0.7217 Shares Of AcelRx Common Stock, 1 Contingent Value Right",2020-05-27 09:56:00-04:00,ACRX,positive
19284.0,AcelRx Reports Revised Consideration For Tetraphase Deal: $30M In Stock And Cash Plus Added $14.5M In Contingent Value Rights Payable In Cash,2020-05-27 09:55:00-04:00,ACRX,positive
19285.0,"The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray",2020-05-22 07:10:00-04:00,ACRX,neutral
19286.0,UPDATE: Tetraphase Board Determine Melinta Offer Could Reasonably Be Expected To Lead To A Superior Offer As Defined In AcelRx Deal,2020-05-15 06:40:00-04:00,ACRX,positive
19287.0,Tetraphase  Says On May 12 Received Revised Proposal From La Jolla Pharmaceutical For $22.3M In Cash Plus Additional $12.5M In Cash Under Contingent Value; Co.'s Board At This Time Continues To Recommend AcelRx Merger Agreement,2020-05-13 06:23:00-04:00,ACRX,positive
19288.0,"AcelRx Pharmaceuticals Q1 EPS $(0.200) Misses $(0.170) Estimate, Sales $386.000K Up From $265.000K YoY",2020-05-11 16:16:00-04:00,ACRX,negative
19289.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,ACRX,neutral
19290.0,Bidding War Sends Tetraphase Shares Soaring,2020-05-07 12:55:00-04:00,ACRX,negative
19291.0,"The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500",2020-05-07 07:41:00-04:00,ACRX,negative
19292.0,AcelRx shares are trading higher after the company announced DSUVIA has received Milestone C approval.,2020-04-30 07:37:00-04:00,ACRX,positive
19293.0,20 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-04-30 07:33:00-04:00,ACRX,neutral
19294.0,AcelRx Announces DSUVIA® Milestone C Approval,2020-04-30 06:07:00-04:00,ACRX,positive
19295.0,"The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test",2020-03-24 08:20:00-04:00,ACRX,negative
19296.0,"H.C. Wainwright Maintains Buy on AcelRx Pharmaceuticals, Lowers Price Target to $7",2020-03-17 08:36:00-04:00,ACRX,negative
19297.0,AcelRx Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 sales results.,2020-03-16 12:31:00-04:00,ACRX,neutral
19298.0,AcelRx Pharmaceuticals: Q4 Earnings Insights,2020-03-16 09:02:00-04:00,ACRX,neutral
19299.0,"AcelRx Pharmaceuticals Q4 EPS $(0.18) Beats $(0.2) Estimate, Sales $475K Miss $1.01M Estimate",2020-03-16 07:44:00-04:00,ACRX,negative
19300.0,AcelRx Pharmaceuticals To Acquire Tetraphase Pharmaceuticals For 0.6303 AcelRx Shares For Each Share Of Tetraphase,2020-03-16 07:31:00-04:00,ACRX,positive
19301.0,"The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review",2020-03-15 09:55:00-04:00,ACRX,neutral
19302.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,ACRX,negative
19303.0,AcelRx Announces Confirmed Timing Of Department Of Defense Milestone C Meeting For April,2020-03-10 14:27:00-04:00,ACRX,positive
19304.0,AcelRx Announces Agreement For Investigator-Initiated Study Of DSUVIA In Patients Undergoing Spine Surgery,2020-03-06 11:56:00-05:00,ACRX,positive
19305.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,ACRX,neutral
19306.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,ACRX,negative
19307.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,ACRX,positive
19308.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,ACRX,negative
19309.0,Stocks That Hit 52-Week Lows On Tuesday,2020-02-25 10:22:00-05:00,ACRX,negative
19310.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,ACRX,negative
19311.0,"The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion",2020-02-21 07:46:00-05:00,ACRX,negative
19312.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,ACRX,negative
19313.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,ACRX,negative
19314.0,Stocks That Hit 52-Week Lows On Tuesday,2020-02-18 11:11:00-05:00,ACRX,negative
19315.0,"AcelRx Sees Prelim. FY19 Sales $2.3M, Cash, Cash Equivalents And Short-Term Investments Of $66.1M As Of Dec. 31",2020-01-13 07:18:00-05:00,ACRX,neutral
19316.0,70 Biggest Movers From Yesterday,2019-12-12 06:31:00-05:00,ACRX,neutral
19317.0,"The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate",2019-11-22 08:18:00-05:00,ACRX,positive
19318.0,Stocks That Hit 52-Week Lows On Wednesday,2019-11-13 10:50:00-05:00,ACRX,negative
19319.0,AcelRx Pharmaceuticals Announces Publication Analyzing Pooled Dosing and Efficacy Data on Sufentanil Sublingual 30 mcg Tablets,2019-11-13 07:05:00-05:00,ACRX,neutral
19320.0,Stocks That Hit 52-Week Lows On Tuesday,2019-11-12 10:52:00-05:00,ACRX,negative
19321.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,ACRX,neutral
19322.0,Stocks That Hit 52-Week Lows On Monday,2019-11-11 10:45:00-05:00,ACRX,negative
19323.0,"Benzinga's Top Upgrades, Downgrades For November 11, 2019",2019-11-11 09:38:00-05:00,ACRX,positive
19324.0,10 Biggest Price Target Changes For Monday,2019-11-11 08:42:00-05:00,ACRX,neutral
19325.0,"Credit Suisse Downgrades AcelRx Pharmaceuticals to Neutral, Lowers Price Target to $2",2019-11-11 07:23:00-05:00,ACRX,positive
19326.0,Stocks That Hit 52-Week Lows On Thursday,2019-11-07 12:16:00-05:00,ACRX,negative
19327.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,ACRX,negative
19328.0,"AcelRx Pharmaceuticals Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $608K Miss $960K Estimate",2019-11-06 16:56:00-05:00,ACRX,negative
19329.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,ACRX,positive
19330.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,ACRX,neutral
19331.0,"AcelRx Pharmaceuticals Q2 EPS $(0.16) Beats $(0.22) Estimate, Sales $941K Miss $1.1M Estimate",2019-08-05 16:45:00-04:00,ACRX,negative
19332.0,"Credit Suisse Assumes AcelRx Pharmaceuticals at Outperform, Announces $7 Price Target",2019-08-05 08:43:00-04:00,ACRX,positive
19333.0,45 Healthcare Stocks Moving In Monday's After-Market Session,2019-07-30 04:54:00-04:00,ACRX,neutral
19334.0,62 Biggest Movers From Friday,2019-07-29 05:47:00-04:00,ACRX,neutral
19335.0,35 Stocks Moving In Thursday's Pre-Market Session,2019-07-11 08:21:00-04:00,ACRX,neutral
19336.0,Credit Suisse Assumes AcelRx Pharmaceuticals at Outperform,2019-07-10 09:28:00-04:00,ACRX,positive
19337.0,60 Biggest Movers From Friday,2019-07-01 05:01:00-04:00,ACRX,neutral
19338.0,40 Stocks Moving In Friday's Mid-Day Session,2019-06-28 12:19:00-04:00,ACRX,neutral
19339.0,64 Biggest Movers From Yesterday,2019-05-30 05:08:00-04:00,ACRX,neutral
19340.0,"AcelRx Pharmaceuticals Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $265K Miss $750K Estimate",2019-05-08 16:33:00-04:00,ACRX,negative
19341.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,ACRX,negative
19342.0,26 Stocks Moving In Monday's Pre-Market Session,2019-05-06 08:07:00-04:00,ACRX,neutral
19343.0,"B. Riley FBR Initiates Coverage On AcelRx Pharmaceuticals, Inc. - Common Stock with Buy Rating",2019-04-24 06:30:00-04:00,ACRX,neutral
19344.0,"Acelrx Pharmaceutical's Pooled Safety Results For Sufentanil Sublingual Tablets Selected For Presentation At 44Th Annual Regional Anesthesiology & Acute Pain Medicine Meeting Redwood City, Calif., April 11, 2019",2019-04-11 16:44:00-04:00,ACRX,negative
19345.0,AcelRx Pharmaceuticals To Present At Oppenheimer & Co. Inc. 29th Annual Healthcare Conference,2019-03-11 16:03:00-04:00,ACRX,neutral
19346.0,70 Biggest Movers From Friday,2019-03-11 05:26:00-04:00,ACRX,neutral
19347.0,AcelRx Pharmaceuticals shares are trading lower after the company reported less-than-expected Q4 sales results.,2019-03-08 11:43:00-05:00,ACRX,neutral
19348.0,"The Daily Biotech Pulse: Tonix Gets European Patent, EC Nod For Roche, Insys Earnings",2019-03-08 07:38:00-05:00,ACRX,neutral
19349.0,"AcelRx Pharmaceuticals Q4 EPS $(0.18) Beats $(0.20) Estimate, Sales $613K Miss $1.51M Estimate",2019-03-07 16:12:00-05:00,ACRX,negative
19350.0,"Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO",2019-03-07 07:48:00-05:00,ACRX,negative
19351.0,81 Biggest Movers From Friday,2019-03-04 05:39:00-05:00,ACRX,neutral
19352.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-03-03 09:41:00-05:00,ACRX,neutral
19353.0,64 Stocks Moving In Friday's Mid-Day Session,2019-03-01 13:18:00-05:00,ACRX,neutral
19354.0,71 Biggest Movers From Yesterday,2019-02-20 04:49:00-05:00,ACRX,neutral
19355.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-02-19 13:01:00-05:00,ACRX,neutral
19356.0,61 Biggest Movers From Friday,2019-02-19 05:14:00-05:00,ACRX,neutral
19357.0,52 Stocks Moving In Friday's Mid-Day Session,2019-02-15 12:35:00-05:00,ACRX,neutral
19358.0,"Benzinga's Top Upgrades, Downgrades For February 15, 2019",2019-02-15 09:16:00-05:00,ACRX,positive
19359.0,"Credit Suisse Initiates Coverage On AcelRx Pharmaceuticals with Outperform Rating, Announces $7 Price Target",2019-02-15 08:34:00-05:00,ACRX,positive
19360.0,31 Stocks Moving In Friday's Pre-Market Session,2019-02-15 08:20:00-05:00,ACRX,neutral
19361.0,"AcelRx Pharma Reports DSUVIA Will Be Highlighted During Presentation At Boswick Burn, Wound Symposium",2019-01-31 07:18:00-05:00,ACRX,neutral
19362.0,40 Stocks Moving In Friday's Pre-Market Session,2019-01-18 08:07:00-05:00,ACRX,neutral
19363.0,28 Stocks Moving In Monday's Pre-Market Session,2018-12-24 08:02:00-05:00,ACRX,neutral
19364.0,AcelRx Pharmaceuticals Added To NASDAQ Biotechnology Index,2018-12-18 07:05:00-05:00,ACRX,neutral
19365.0,31 Stocks Moving In Monday's Pre-Market Session,2018-12-10 08:16:00-05:00,ACRX,neutral
19366.0,21 Stocks Moving In Monday's Pre-Market Session,2018-11-26 07:53:00-05:00,ACRX,neutral
19367.0,50 Biggest Movers From Yesterday,2018-11-21 05:49:00-05:00,ACRX,neutral
19368.0,Shares of AcelRx Pharmaceuticals are trading up 10.3% after the Chief Medical Officer bought 16k shares at $3.07/share.,2018-11-20 14:17:00-05:00,ACRX,positive
19369.0,36 Stocks Moving In Tuesday's Mid-Day Session,2018-11-20 12:34:00-05:00,ACRX,neutral
19370.0,"Acelrx Pharmaceuticals CFO Asadorian Buys 5,000 @ Avg Price: $3.13",2018-11-13 13:55:00-05:00,ACRX,neutral
19371.0,85 Biggest Movers From Friday,2018-11-12 05:16:00-05:00,ACRX,neutral
19372.0,68 Stocks Moving In Friday's Mid-Day Session,2018-11-09 12:42:00-05:00,ACRX,neutral
19373.0,AcelRx Prices ~12.7M Share Common Stock Offering At $3.15/Share,2018-11-09 09:11:00-05:00,ACRX,positive
19374.0,Hearing AcelRx Pharma Offering Priced At $3.15/Share,2018-11-09 08:58:00-05:00,ACRX,neutral
19375.0,34 Stocks Moving In Friday's Pre-Market Session,2018-11-09 08:15:00-05:00,ACRX,neutral
19376.0,"AcelRx Reports Offering Of Common Shares, No Terms Disclosed",2018-11-09 07:09:00-05:00,ACRX,neutral
19377.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Mon., Nov. 5, 2018",2018-11-05 10:43:00-05:00,ACRX,positive
19378.0,24 Stocks Moving In Monday's Pre-Market Session,2018-11-05 08:03:00-05:00,ACRX,neutral
19379.0,74 Biggest Movers From Friday,2018-11-05 04:36:00-05:00,ACRX,neutral
19380.0,"AcelRx Pharmaceuticals Q3 EPS $(0.21) Up From $(0.28) YoY, Sales $377K Down From $1.487M YoY",2018-11-02 16:06:00-04:00,ACRX,neutral
19381.0,"Ladenburg Thalmann Reiterates Buy And $100 Price Target On AcelRx Following FDA Approval Of DSUVIA; Firm Says Approval Supports Firm's Expectations, Not Making Any Changes To Revenue Estimates",2018-11-02 15:14:00-04:00,ACRX,positive
19382.0,AcelRx shares are trading up 7% after the FDA approved the company's DSUVIA pain medication.,2018-11-02 14:16:00-04:00,ACRX,positive
19383.0,AcelRx Shares Resume Trade,2018-11-02 14:15:00-04:00,ACRX,positive
19384.0,AcelRx Shares To Resume Trade At 2:15 p.m. ET,2018-11-02 14:01:00-04:00,ACRX,positive
19385.0,AcelRx Press Release Confirms FDA Approval For DSUVIA,2018-11-02 13:57:00-04:00,ACRX,positive
19386.0,AcelRx Says Sees US Launch Of DSUVIA In Q1'19,2018-11-02 13:54:00-04:00,ACRX,neutral
19387.0,"UPDATE: FDA Commissioner Scott Gottlieb Says There Are 'Very Tight Restrictions' Being Placed On Distribution And Use Of Dsuvia, Says FDA Will Continue To Monitor Implementation Or Risk Evaluation And Mitigation Strategy Associated With Drug",2018-11-02 13:43:00-04:00,ACRX,negative
19388.0,"FDA Has Approved AcelRx's Pain Medication, Dsuvia",2018-11-02 13:40:00-04:00,ACRX,negative
19389.0,AcelRx Shares Halted News Pending,2018-11-02 12:55:00-04:00,ACRX,positive
19390.0,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,2018-11-01 09:26:00-04:00,ACRX,neutral
19391.0,"Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?",2018-10-29 13:10:00-04:00,ACRX,positive
19392.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,ACRX,neutral
19393.0,30 Stocks Moving In Friday's Pre-Market Session,2018-10-26 08:06:00-04:00,ACRX,neutral
19394.0,31 Stocks Moving In Thursday's Pre-Market Session,2018-10-25 08:03:00-04:00,ACRX,neutral
19395.0,56 Biggest Movers From Yesterday,2018-10-24 05:53:00-04:00,ACRX,neutral
19396.0,"B. Riley FBR Initiates Coverage On AcelRx Pharmaceuticals with Buy Rating, Announces $9 Price Target",2018-10-23 07:28:00-04:00,ACRX,neutral
19397.0,30 Stocks Moving In Monday's Pre-Market Session,2018-10-22 08:05:00-04:00,ACRX,neutral
19398.0,58 Biggest Movers From Friday,2018-10-22 05:11:00-04:00,ACRX,neutral
19399.0,Aclaris Therapeutics shares are down 6.0% after the company reported a common stock offering.,2018-10-17 17:09:00-04:00,ACRX,positive
19400.0,48 Biggest Movers From Yesterday,2018-10-17 05:53:00-04:00,ACRX,neutral
19401.0,"10 Hottest Stocks From October 16, 2018",2018-10-16 16:33:00-04:00,ACRX,neutral
19402.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Tues., Oct. 16, 2018",2018-10-16 15:36:00-04:00,ACRX,positive
19403.0,40 Stocks Moving In Tuesday's Mid-Day Session,2018-10-16 12:46:00-04:00,ACRX,neutral
19404.0,26 Stocks Moving In Tuesday's Pre-Market Session,2018-10-16 08:12:00-04:00,ACRX,neutral
19405.0,42 Biggest Movers From Yesterday,2018-10-16 05:27:00-04:00,ACRX,neutral
19406.0,"10 Hottest Stocks From October 15, 2018",2018-10-15 17:26:00-04:00,ACRX,neutral
19407.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Mon., Oct. 15, 2018",2018-10-15 16:35:00-04:00,ACRX,positive
19408.0,AcelRx Pharmaceuticals Option Alert: Nov 16 $5 Calls Sweep (5) near the Bid: 502 @ $0.551 vs 4657 OI; Earnings 11/8 After Close [est] Ref=$4.235,2018-10-15 14:52:00-04:00,ACRX,positive
19409.0,35 Stocks Moving In Monday's Mid-Day Session,2018-10-15 12:47:00-04:00,ACRX,neutral
19410.0,AcelRx Pharmaceuticals Option Alert: Dec 21 $5 Calls at the Bid: 4213 @ $0.7 vs 8706 OI; Earnings 11/8 After Close [est] Ref=$4.3469,2018-10-15 12:12:00-04:00,ACRX,positive
19411.0,Mid-Day Market Update: Cambium Learning Surges On Acquisition News; CPI Aerostructures Shares Drop,2018-10-15 12:10:00-04:00,ACRX,neutral
19412.0,Mid-Morning Market Update: Markets Open Lower; Bank of America Earnings Beat Expectations,2018-10-15 10:14:00-04:00,ACRX,negative
19413.0,"Benzinga's Top Upgrades, Downgrades For October 15, 2018",2018-10-15 09:27:00-04:00,ACRX,positive
19414.0,22 Stocks Moving In Monday's Pre-Market Session,2018-10-15 08:07:00-04:00,ACRX,neutral
19415.0,"Jefferies Upgrades AcelRx Pharmaceuticals to Buy, Announces $8 Price Target",2018-10-15 07:19:00-04:00,ACRX,neutral
19416.0,A Peek Into The Markets: US Stock Futures Down Ahead Of Retail Sales Data,2018-10-15 07:16:00-04:00,ACRX,neutral
19417.0,44 Biggest Movers From Yesterday,2018-10-15 05:06:00-04:00,ACRX,neutral
19418.0,"5 Stocks To Watch For October 15, 2018",2018-10-15 04:53:00-04:00,ACRX,neutral
19420.0,"AcelRX Pharma Shares Resume Trade, Up 10.7%",2018-10-12 16:45:00-04:00,ACRX,positive
19421.0,AcelRX Pharma Shares To Resume Trade at 4:45pm ET,2018-10-12 16:30:00-04:00,ACRX,positive
19422.0,AcelRX Pharma FDA AdCom Votes 10-3 In Favor Approval of DSUVIA,2018-10-12 16:16:00-04:00,ACRX,positive
19423.0,41 Stocks Moving In Friday's Mid-Day Session,2018-10-12 13:42:00-04:00,ACRX,neutral
19424.0,20 Stocks Moving In Friday's Pre-Market Session,2018-10-12 08:20:00-04:00,ACRX,neutral
19425.0,"The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",2018-10-12 07:34:00-04:00,ACRX,negative
19426.0,AcelRx Pharma Shares Halted Ahead Of FDA AdCom Panel For DSUVIA,2018-10-12 07:13:00-04:00,ACRX,positive
19427.0,AcelRx Pharma Shares Halted News Pending,2018-10-12 06:55:00-04:00,ACRX,positive
19428.0,44 Biggest Movers From Yesterday,2018-10-12 04:45:00-04:00,ACRX,neutral
19429.0,41 Biggest Movers From Yesterday,2018-10-11 05:22:00-04:00,ACRX,neutral
19430.0,"10 Hottest Stocks From October 10, 2018",2018-10-10 17:18:00-04:00,ACRX,neutral
19431.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Wed., Oct. 10, 2018",2018-10-10 16:25:00-04:00,ACRX,positive
19432.0,41 Stocks Moving In Wednesday's Mid-Day Session,2018-10-10 12:54:00-04:00,ACRX,neutral
19433.0,AcelRx Shares React Positively To FDA Committee Briefing On Painkiller Candidate Dsuvia,2018-10-10 12:32:00-04:00,ACRX,positive
19434.0,"AcelRx Pharmaceuticals are up 26%; Shares dipped in the pre-market session amid reports of negative FDA comments on the company's Dsuvia, although analysts at Ladenburg Thalmann reiterated a Buy rating and raised the stock's price target to $10.",2018-10-10 10:32:00-04:00,ACRX,negative
19435.0,"Ladenburg Thalmann Reiterates Buy on AcelRx Pharmaceuticals, Raises Price Target to $10",2018-10-10 09:59:00-04:00,ACRX,neutral
19436.0,"AcelRx Pharma Shares Fall 50.9%; Hearing FDA Staff Has Highlighted Co.'s Dsuvia Offers 'No Apparent Advantage Over Currently Available Therapies,' FDA Staff Highlights Risks Of Misplaced Tablets Of Dsuvia",2018-10-10 08:15:00-04:00,ACRX,neutral
19437.0,30 Stocks Moving In Wednesday's Pre-Market Session,2018-10-10 08:02:00-04:00,ACRX,neutral
19438.0,46 Biggest Movers From Yesterday,2018-10-10 05:08:00-04:00,ACRX,neutral
19439.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs",2018-10-08 07:30:00-04:00,ACRX,neutral
19440.0,45 Biggest Movers From Yesterday,2018-10-03 05:40:00-04:00,ACRX,neutral
19441.0,Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates,2018-09-26 16:41:00-04:00,ACRX,neutral
19442.0,51 Biggest Movers From Yesterday,2018-09-25 04:53:00-04:00,ACRX,neutral
19443.0,AcelRx Announces October 12 Date Of FDA Advisory Committee Meeting For DSUVIA,2018-09-11 07:04:00-04:00,ACRX,neutral
19444.0,"AcelRX Shares Should More Than Double On Painkiller Assets, Landenburg Says In Bullish Initiation",2018-08-16 11:19:00-04:00,ACRX,positive
19445.0,"Benzinga's Top Upgrades, Downgrades For August 16, 2018",2018-08-16 08:54:00-04:00,ACRX,positive
19446.0,"Ladenburg Thalmann Initiates Coverage On AcelRx Pharmaceuticals with Buy Rating, Announces $7 Price Target",2018-08-16 08:12:00-04:00,ACRX,neutral
19447.0,66 Biggest Movers From Friday,2018-08-06 05:36:00-04:00,ACRX,neutral
19448.0,56 Stocks Moving In Friday's Mid-Day Session,2018-08-03 12:27:00-04:00,ACRX,neutral
19449.0,"AcelRx Pharmaceuticals Q2 EPS $(0.20), Inline, Sales $818K Miss $910K Estimate",2018-08-02 16:25:00-04:00,ACRX,negative
19450.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,ACRX,positive
19451.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,ACRX,neutral
19452.0,23 Stocks Moving In Monday's Pre-Market Session,2018-07-23 08:03:00-04:00,ACRX,neutral
19453.0,Oppenheimer Initiates Coverage On AcelRx Pharmaceuticals with Perform Rating,2018-07-13 09:17:00-04:00,ACRX,neutral
19454.0,44 Biggest Movers From Yesterday,2018-07-13 04:08:00-04:00,ACRX,neutral
19455.0,30 Stocks Moving In Thursday's Mid-Day Session,2018-07-12 12:19:00-04:00,ACRX,neutral
19456.0,Mid-Morning Market Update: Markets Open Higher; Delta Air Lines Earnings Beat Estimates,2018-07-12 10:26:00-04:00,ACRX,neutral
19457.0,AcelRx Pharma Prices ~7.27M Share Common Stock Offering At $2.75/Share,2018-07-12 09:33:00-04:00,ACRX,positive
19458.0,"Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial",2018-07-12 08:37:00-04:00,ACRX,neutral
19459.0,25 Stocks Moving In Thursday's Pre-Market Session,2018-07-12 08:00:00-04:00,ACRX,neutral
19460.0,"7 Stocks To Watch For July 12, 2018",2018-07-12 04:50:00-04:00,ACRX,neutral
19461.0,6 Stocks Moving In Wednesday's After-Hours Session,2018-07-11 16:58:00-04:00,ACRX,neutral
19462.0,"AcelRx Pharma 8-K Shows Expectation For ~$50M In Cash, Cash Equivalents, Short-Term Investments As Of Jun. 30, 2018",2018-07-11 16:23:00-04:00,ACRX,neutral
19463.0,AcelRx Pharmaceuticals Announces Commencement Of Common Stock Offering; No Size Disclosed,2018-07-11 16:08:00-04:00,ACRX,negative
19464.0,23 Stocks Moving In Wednesday's Pre-Market Session,2018-06-27 07:58:00-04:00,ACRX,neutral
19465.0,AcelRx Receives European Commission Approval for DZUVEO,2018-06-27 07:01:00-04:00,ACRX,positive
19466.0,"Analyst: AcelRx Will Address FDA Concerns, Secure Approval This Year",2018-06-12 12:19:00-04:00,ACRX,positive
19467.0,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate",2018-06-12 08:47:00-04:00,ACRX,positive
19468.0,"Cantor Fitzgerald Initiates Coverage On 8 Pharma/Biotech Stocks After Hours: 7 With Overweight, 1 With Neutral Rating",2018-06-11 16:54:00-04:00,ACRX,negative
19469.0,Leerink Revelation Healthcare Fund Reports 7.3% Stake In AcelRx,2018-05-31 11:21:00-04:00,ACRX,neutral
19470.0,45 Biggest Movers From Yesterday,2018-05-25 04:37:00-04:00,ACRX,neutral
19471.0,42 Stocks Moving In Thursday's Mid-Day Session,2018-05-24 13:31:00-04:00,ACRX,neutral
19472.0,AcelRx Earlier Announced That FDA Accepted Resubmission Of NDA For Co.'s DSUVIA Pain Mangement Therapy; Shares Up 11.1% Premarket,2018-05-24 09:09:00-04:00,ACRX,neutral
19473.0,25 Stocks Moving In Thursday's Pre-Market Session,2018-05-24 08:40:00-04:00,ACRX,neutral
19474.0,AcelRx Pharma Reports All Of Co. Shares Owned By Three Arch Partners Were Purchased By Investors Led By Leerink revelation Partners; Included ~9.37M Shares Across All Funds; Co. Did Not Receive Proceeds From Sale,2018-05-23 07:09:00-04:00,ACRX,positive
19475.0,23 Stocks Moving In Monday's Pre-Market Session,2018-05-21 08:03:00-04:00,ACRX,neutral
19476.0,"AcelRx Pharmaceuticals Shares Up 10.8% On Heavy Volume, No Apparent News",2018-05-15 14:09:00-04:00,ACRX,neutral
19477.0,"AcelRx Pharmaceuticals Q1 EPS $(0.23) Beats $(0.24) Estimate, Sales $343K Miss $1.15M Estimate",2018-05-09 17:38:00-04:00,ACRX,negative
19478.0,"Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway",2018-05-09 07:48:00-04:00,ACRX,neutral
19479.0,AcelRx resubmits New Drug Application for DSUVIA,2018-05-09 07:01:00-04:00,ACRX,neutral
19480.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,ACRX,neutral
19481.0,AcelRx Pharma Announces the Publication of a Study Funded by the Company,2018-04-30 07:13:00-04:00,ACRX,neutral
19482.0,AcelRx Pharma Shares Up 13% Premarket; Co. Earlier Announced Positive CHMP Opinion For DZUVEO For Mgmt. Of Acute Moderate To Severe Pain In Medically Monitored Settings,2018-04-27 08:12:00-04:00,ACRX,neutral
19483.0,AcelRx Pharma Announces Publication that Sublingual Sufentanil Tablets Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting,2018-04-18 07:05:00-04:00,ACRX,negative
19484.0,11 Stocks Moving In Monday's After-Hours Session,2018-04-16 17:28:00-04:00,ACRX,neutral
19485.0,AcelRx Confirms Plans to Resubmit NDA in Q2 2018,2018-04-16 07:06:00-04:00,ACRX,neutral
19486.0,41 Biggest Movers From Yesterday,2018-03-27 05:46:00-04:00,ACRX,neutral
19487.0,44 Biggest Movers From Friday,2018-03-12 04:59:00-04:00,ACRX,neutral
19488.0,36 Stocks Moving In Friday's Mid-Day Session,2018-03-09 12:41:00-05:00,ACRX,neutral
19489.0,AcelRX Shares Up 10.3% After Co. Announced Planned Resubmission Of NDA For DSUVIA In Q2,2018-03-09 12:06:00-05:00,ACRX,positive
19490.0,26 Stocks Moving In Friday's Pre-Market Session,2018-03-09 08:07:00-05:00,ACRX,neutral
19491.0,AcelRX Shares Up 7.6% After Hours As Co. Plans Resubmission Of NDA For DSUVIA In Q2,2018-03-08 16:19:00-05:00,ACRX,positive
19492.0,"AcelRx Pharmaceuticals Reports Q4 EPS $(0.20) vs $(0.20) Est., Sales $740K",2018-03-08 16:13:00-05:00,ACRX,neutral
19493.0,"AcelRx Highlights Publication of Manuscript Analyzing Sufentanil Sublingual Tablets in Patients with Postoperative Pain, Showed '30 mcg tablet was effective and well-tolerated for the management of moderate-to-severe acute pain...'",2017-11-16 07:11:00-05:00,ACRX,negative
19494.0,"AcelRx Pharmaceuticals Reports Q3 EPS $(0.28) vs $(0.27) Est.,Sales $1.48M vs $2.22M Est.",2017-11-09 16:03:00-05:00,ACRX,neutral
19495.0,25 Stocks Moving In Monday's Pre-Market Session,2017-10-23 08:03:00-04:00,ACRX,neutral
19496.0,AcelRx +10% Premarket @$2.20; Co Announced Friday DSUVIA Clinical Trial Results Selected as a Top Abstract for Oral Presentation at ASA's Annual Meeting,2017-10-23 06:22:00-04:00,ACRX,positive
19497.0,AcelRx Reports DSUVIA Trial Results Selected As Top Abstract for Oral Presentation At ASA Annual Meeting,2017-10-20 08:05:00-04:00,ACRX,positive
19498.0,"Pharma Stock Roundup: Pfizer Mulls Options For Consumer Healthcare, Eli Lilly's Pipeline Setback",2017-10-13 12:19:00-04:00,ACRX,neutral
19499.0,"Benzinga's Top Upgrades, Downgrades For October 13, 2017",2017-10-13 09:14:00-04:00,ACRX,positive
19500.0,"The Market In 5 Minutes: Trump To End Key ACA Subsidies, McGowan Speaks Out, Amazon Studio Exec Suspended",2017-10-13 08:34:00-04:00,ACRX,negative
19501.0,28 Stocks Moving In Friday's Pre-Market Session,2017-10-13 08:03:00-04:00,ACRX,neutral
19502.0,Jefferies Downgrades AcelRx Pharmaceuticals to Hold,2017-10-13 06:08:00-04:00,ACRX,neutral
19503.0,Mid-Afternoon Market Update: Crude Oil Down 2%; Infinity Pharmaceuticals Shares Spike Higher,2017-10-12 14:30:00-04:00,ACRX,negative
19504.0,33 Stocks Moving In Thursday's Mid-Day Session,2017-10-12 12:40:00-04:00,ACRX,neutral
19505.0,Mid-Day Market Update: J.Jill Tumbles Following Weak Q3 Outlook; Ardelyx Shares Surge,2017-10-12 12:22:00-04:00,ACRX,negative
19506.0,Mid-Morning Market Update: Markets Edge Lower; JPMorgan Profit Beats Estimates,2017-10-12 10:14:00-04:00,ACRX,positive
19507.0,30 Stocks Moving In Thursday's Pre-Market Session,2017-10-12 08:03:00-04:00,ACRX,neutral
19508.0,AcelRx Pharma Gets a Complete Response Letter from the FDA,2017-10-12 06:47:00-04:00,ACRX,neutral
19509.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-10-11 08:22:00-04:00,ACRX,neutral
19510.0,AcelRX Pharma Shares Up 5.29% On Heavy Volume Ahead Of Thursday PDUFA Date For DSUVIA,2017-10-10 11:36:00-04:00,ACRX,positive
19511.0,"The Week Ahead: New IPOs, Bank Earnings, And Some Notable FDA Actions",2017-10-09 10:31:00-04:00,ACRX,neutral
19512.0,"Watching Flexion, AxelRx, Agile Therapeutics Shares Premarket Thurs. Following Reuters Highlighting 'RBC sees 3 small-cap drugmakers as candidates for takeover'; Stocks Not Moving",2017-10-05 07:20:00-04:00,ACRX,positive
19513.0,Early FDA Approval Speculation Sends AcelRX Pharma Shares Soaring,2017-10-02 15:55:00-04:00,ACRX,positive
19514.0,20 Biggest Mid-Day Gainers For Monday,2017-10-02 12:04:00-04:00,ACRX,neutral
19515.0,Mid-Morning Market Update: Markets Open Higher; Cal-Maine Foods Posts Wider-Than-Expected Loss,2017-10-02 10:12:00-04:00,ACRX,negative
19516.0,"AcelRx Shares Up 5.5% Premarket; Biotech Investor And Head Of IP For DSM Sinochem Pharma, James DeYonker On Twitter Speculates About Possible Early PDUFA Approval",2017-10-02 08:55:00-04:00,ACRX,positive
19517.0,30 Stocks Moving In Monday's Pre-Market Session,2017-10-02 08:11:00-04:00,ACRX,neutral
19518.0,"FDA Says It Sent Letters To 74 Manufacturers Of Opioid Analgesics Intended For Outpatient Use, Will Soon Issue Guidance For Applicants Seeking Approval For Generic Versions Of Abuse-Deterrent Opioids",2017-09-28 15:03:00-04:00,ACRX,positive
19519.0,"Attention Biotech Investors, Here's Your PDUFA Primer For October",2017-09-28 10:51:00-04:00,ACRX,neutral
19520.0,18 Biggest Mid-Day Gainers For Tuesday,2017-09-26 12:37:00-04:00,ACRX,neutral
19521.0,Born On The Battlefield: AcelRx Awaits FDA Ruling On Device That Delivers Potent Opioid To Wounded Soldiers,2017-08-30 12:07:00-04:00,ACRX,negative
19522.0,12 Biggest Mid-Day Gainers For Tuesday,2017-08-29 12:21:00-04:00,ACRX,neutral
19523.0,13G/A Filing From Perceptive Advisors Shows 2.7% Stake In AcelRX Pharmaceuticals,2017-08-23 16:36:00-04:00,ACRX,neutral
19524.0,AcelRx Shares Pop to High of $3.10; Traders Circulate Agora Note With $9 PT,2017-08-09 15:29:00-04:00,ACRX,positive
19525.0,18 Biggest Mid-Day Losers For Wednesday,2017-08-02 12:52:00-04:00,ACRX,negative
19526.0,Mid-Afternoon Market Update: Crude Oil Down 2.5%; Horizon Global Shares Spike Higher,2017-08-01 14:30:00-04:00,ACRX,negative
19527.0,15 Biggest Mid-Day Losers For Tuesday,2017-08-01 13:10:00-04:00,ACRX,negative
19528.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-08-01 08:04:00-04:00,ACRX,neutral
19529.0,"AcelRx Pharmaceuticals Reports Q2 EPS $(0.29) vs $(0.28) Est., Sales $2.65M vs $2.27M Est.",2017-08-01 07:11:00-04:00,ACRX,neutral
19530.0,"AcelRx Pharmaceuticals Reports Successful Outcome of ZALVISO Phase 3 IAP312 Study on Device Functionality, AcelRx Remains on Track to Resubmit NDA by End of 2017",2017-08-01 07:07:00-04:00,ACRX,positive
19531.0,18 Biggest Mid-Day Gainers For Monday,2017-07-24 12:24:00-04:00,ACRX,neutral
19532.0,Mid-Morning Market Update: Markets Mostly Flat; Philip Morris Profit Misses Estimates,2017-07-20 10:15:00-04:00,ACRX,positive
19533.0,AcelRx Pharmaceuticals Names Raffi Asadorian CFO,2017-07-19 07:00:00-04:00,ACRX,neutral
19534.0,18 Biggest Mid-Day Gainers For Monday,2017-07-17 12:30:00-04:00,ACRX,neutral
19535.0,20 Stocks Moving In Monday's Pre-Market Session,2017-07-17 08:19:00-04:00,ACRX,neutral
19536.0,S-3 from AcelRx Pharma Shows Registration for $150M Mixed Securities Shelf Offering,2017-06-05 17:04:00-04:00,ACRX,positive
19537.0,AcelRX CFO Resigns,2017-06-05 06:38:00-04:00,ACRX,negative
19538.0,"AcelRx Pharma Reports Q1 EPS $(0.34) vs $(0.27) Est., Sales $3.109M vs $1.8M Est.",2017-05-08 16:01:00-04:00,ACRX,neutral
19539.0,Mid-Day Market Update: Dow Drops Over 100 Points; Arena Pharmaceuticals Shares Plummet,2017-04-18 12:01:00-04:00,ACRX,positive
19540.0,SIRF Report's Roddy Boyd Tweets: This DSuvia thing = a real test of FDA resolve as there's no apparent medical need for it @acelrx_pharma,2017-04-17 10:26:00-04:00,ACRX,positive
19541.0,"SIRF Reporter Roddy Boyd Tweets: The next chap in unexpected prescription deaths I'll be covering: @acelrx_pharma Dsuvia sublingual tablets, ~10x stronger than Fentanyl",2017-04-17 10:14:00-04:00,ACRX,positive
19542.0,"What Success Is Made Of: Investors, Execs And Entrepreneurs Talk About Their Routines And Role Models - Part 2",2017-04-16 16:33:00-04:00,ACRX,positive
19543.0,"What Success Is Made Of: Investors, Execs And Entrepreneurs Talk Routines And Role Models",2017-04-10 15:33:00-04:00,ACRX,positive
19544.0,AcelRx Reports Comprehensive DSUVIA Trial Results: Says 480 Patients Enrolled Across 4 Late-Phase Studies,2017-04-06 07:02:00-04:00,ACRX,positive
19545.0,AcelRx Pharmaceuticals Announces The EMA Has Notified Company That ARX-04 MAA Passed Validation And Scientific Review Is Underway,2017-03-28 07:09:00-04:00,ACRX,neutral
19546.0,How The Ultra-Wealthy Are Helping Advance Health And Life Sciences,2017-03-10 15:58:00-05:00,ACRX,positive
19547.0,Money Is Energy: A Profile Of Family Office And Silk Legend Thomas Gütermann,2017-03-08 15:43:00-05:00,ACRX,positive
19548.0,Family Office Legend Thomas Gütermann Talks To The Media For The First Time Ever: 'We Opened A Fund Focused On Pre-IPO Unicorns',2017-03-03 12:10:00-05:00,ACRX,positive
19549.0,"AcelRx Pharmaceuticals Reports Q4 EPS $(0.21) vs. $(0.24) Est., Sales $6.4M",2017-03-02 16:04:00-05:00,ACRX,neutral
19550.0,AcelRx CFO Shares Update On DoD Relationship And More After FDA Accepted NDA For DSUVIA,2017-02-28 17:45:00-05:00,ACRX,positive
19551.0,15 Biggest Mid-Day Gainers For Monday,2017-02-27 12:48:00-05:00,ACRX,neutral
19552.0,22 Stocks Moving In Monday's Pre-Market Session,2017-02-27 08:20:00-05:00,ACRX,neutral
19553.0,AcelRx Pharmaceuticals Shares Up 6.6% Premarket As Co. Announced NDA For Dsuvia Accepted For Filing With PDUFA Date Of Oct. 12th,2017-02-27 07:28:00-05:00,ACRX,positive
19554.0,AcelRx Pharma Names Vincent Angotti CEO,2017-02-16 16:47:00-05:00,ACRX,neutral
19555.0,"Exclusive: AcelRx Pharma Execs Discuss Stock Performance, Catalysts And Financial Position",2017-02-16 12:16:00-05:00,ACRX,positive
19556.0,AcelRx: Replacing Morphine With Department Of Defense Funding,2017-02-15 11:08:00-05:00,ACRX,positive
19557.0,20 Stocks Moving In Thursday's Pre-Market Session,2017-01-12 08:28:00-05:00,ACRX,neutral
19558.0,AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for DSUVIA for the Treatment of Moderate-to-Severe Acute Pain,2017-01-08 08:08:00-05:00,ACRX,negative
19559.0,AcelRx Pharmaceuticals Announces DSUVIA as Brand Name for ARX-04 in the US,2017-01-08 08:05:00-05:00,ACRX,neutral
19560.0,AcelRx Pharma Submits NDA for ARX-04,2016-12-13 07:16:00-05:00,ACRX,neutral
19561.0,Jefferies London Healthcare Conference Taking Place Today,2016-11-16 10:52:00-05:00,ACRX,neutral
19562.0,"AcelRx Pharmaceuticals Reports Q3 EPS $(0.25) vs. Est. $(0.23), Rev. $3.36M vs. Est. $2.89M",2016-11-01 17:26:00-04:00,ACRX,neutral
19563.0,AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings and Cost Analysis at European Congress on Emergency Medicine,2016-09-28 07:04:00-04:00,ACRX,negative
19564.0,AcelRx Begins Phase 3 Study of Zalviso in Patients with Moderate-to-Severe Acute Post-Operative Pain,2016-09-27 07:01:00-04:00,ACRX,negative
19565.0,Mid-Afternoon Market Update:  Dow Up Over 200 Points; Lakeland Industries Shares Spike Higher,2016-09-15 14:47:00-04:00,ACRX,positive
19566.0,Mid-Afternoon Market Update: Dow Up Over 200 Points; Lakeland Industries Shares Spike Higher,2016-09-15 14:38:00-04:00,ACRX,positive
19567.0,15 Biggest Mid-Day Gainers For Thursday,2016-09-15 12:44:00-04:00,ACRX,neutral
19568.0,Mid-Day Market Update: NASDAQ Rises Over 1%; AcelRx Shares Surge After Positive Results From Its Trial On ARX-04,2016-09-15 12:12:00-04:00,ACRX,positive
19569.0,Mid-Morning Market Update: Markets Rise; Aerie Pharmaceuticals Reports Positive Roclatan Phase 3 Topline Efficacy Results,2016-09-15 10:18:00-04:00,ACRX,positive
19570.0,15 Stocks Moving In Thursday's Pre-Market Session,2016-09-15 08:27:00-04:00,ACRX,neutral
19571.0,A Peek Into The Markets: U.S. Stock Futures Climb Ahead Of Economic Data,2016-09-15 07:36:00-04:00,ACRX,neutral
19572.0,AcelRx Stock Jumps 20% After Positive Results From Its Trial On ARX-04,2016-09-15 07:32:00-04:00,ACRX,positive
19573.0,"AcelRx Reports Positive Results for ARX-04, Says Intends to Submit NDA",2016-09-15 06:31:00-04:00,ACRX,positive
19574.0,"AcelRx Pharma Will Report Topline Results from Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain on Sept. 15, 2016",2016-09-14 16:02:00-04:00,ACRX,negative
19575.0,12 Stocks Moving In Monday's Pre-Market Session,2016-08-15 08:25:00-04:00,ACRX,neutral
19576.0,AcelRx Pharmaceuticals' ARX-04 Final Stage Study Meets Primary Endpoint,2016-08-15 08:11:00-04:00,ACRX,neutral
19577.0,AcelRx +19% Premarket at $4.44 as Phase 3 Trial of ARX-04 Met Primary Endpoint,2016-08-15 07:06:00-04:00,ACRX,neutral
19578.0,"AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced Pain Intensity in ER Patients with Moderate-to-Severe Acute Pain",2016-08-15 07:03:00-04:00,ACRX,negative
19579.0,"AcelRx Pharma Reports Q2 EPS $(0.24) vs $(0.22) Est., Sales $4.531M vs $2.17M Est.",2016-07-28 16:54:00-04:00,ACRX,neutral
19580.0,AcelRx Pharmaceuticals Says Start Date for IAP312 Study was Revised to September 2016 -8K,2016-07-08 06:15:00-04:00,ACRX,neutral
19581.0,AcelRx Says Had $106M in Cash on Hand as of End of Q1,2016-06-28 07:03:00-04:00,ACRX,positive
19582.0,AcelRx Reports Completion of Patient Enrollment in Remaining Phase 3 Studies of ARX-04 for Treatment of Moderate-to-Severe Acute Pain,2016-06-28 07:03:00-04:00,ACRX,negative
19583.0,Filing from AcelRx Shows Registration for $40M Common Stock Offering,2016-06-21 16:35:00-04:00,ACRX,neutral
19584.0,AcelRx Pharmaceuticals SAP301 Study Met Primary Endpoint In Pain Intensity Differences,2016-05-26 07:06:00-04:00,ACRX,negative
19585.0,Seaport Global Upgrades AcelRx Pharmaceuticals to Buy,2016-05-06 07:47:00-04:00,ACRX,neutral
19586.0,AcelRx Pharmaceuticals Presents Subgroup Analysis Demonstrating Positive Results of ARX‑04 by Type of Abdominal Surgery,2016-05-06 07:01:00-04:00,ACRX,positive
19587.0,"AcelRx Reports Q1 EPS $(0.25) vs $(0.20) Est., Sales $3.025M vs $1.62M Est.",2016-05-02 16:18:00-04:00,ACRX,neutral
19588.0,"UPDATE: AcelRX Pharma Says 'We have successfully transitioned ARX-04 into late-stage development, defined the regulatory pathway for ARX-04 and Zalviso in the U.S.'",2016-03-29 16:01:00-04:00,ACRX,positive
19589.0,"AcelRx Pharmaceuticals Names Howard B. Rosen as CEO,  Provides Update on Clinical Development Activities",2016-03-29 16:00:00-04:00,ACRX,neutral
19590.0,"AcelRX Pharma Reports Q4 EPS $(0.24) Vs Est $(0.10), Expects To Submit NDA For ARX-04 In Q4",2016-03-07 16:02:00-05:00,ACRX,neutral
19591.0,AcelRex Pharma Reports Initiation of Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain,2016-03-07 07:09:00-05:00,ACRX,negative
19592.0,"Earnings Scheduled For March 7, 2016",2016-03-07 04:08:00-05:00,ACRX,neutral
19593.0,AcelRx Phase 3 Interim Analysis For Moderate-To-Severe ain ARX-04 Shows Improved Pain Scores,2016-02-25 07:11:00-05:00,ACRX,negative
19594.0,"AcelRx Pharma Reports Presentation of Phase 3 Results from ARX-04 Program at JAB Burn, Wound Care Symposium",2016-02-11 07:07:00-05:00,ACRX,positive
19595.0,Acelrx Spikes to High of $3.33 on Volume,2016-01-26 10:34:00-05:00,ACRX,neutral
19596.0,AcelRx Pharma. Reports Phase 3 Sublingual Data,2016-01-21 07:01:00-05:00,ACRX,neutral
19597.0,AcelRx Pharmaceuticals Announces Anticipated 2016 Milestones for Product Portfolio,2016-01-10 08:04:00-05:00,ACRX,neutral
19598.0,"AcelRx Closes Protocol Review with FDA, Says Plans to Commence Phase 3 Open-Label Study for Zalviso in Q1",2016-01-08 07:02:00-05:00,ACRX,neutral
19599.0,AcelRx Pharmaceuticals Given Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency,2015-12-23 07:00:00-05:00,ACRX,neutral
19600.0,Mid-Day Market Update: Cintas Gains On Earnings Beat; NetApp Shares Slide,2015-12-22 12:20:00-05:00,ACRX,positive
19601.0,AcelRx Pharma. Conducts Meeting With US FDA Pre-NDA,2015-12-14 07:01:00-05:00,ACRX,neutral
19602.0,AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting,2015-11-19 07:09:00-05:00,ACRX,negative
19603.0,AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients,2015-11-04 07:07:00-05:00,ACRX,positive
19604.0,AcelRx Pharmaceuticals Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients,2015-11-04 07:03:00-05:00,ACRX,positive
19605.0,"AcelRx Reports Q3 EPS $0.11 vs. Est. $(0.23), Rev. $15.428M vs. Est. $1.75M; Estimates Not Comp.",2015-10-29 16:13:00-04:00,ACRX,neutral
19606.0,AcelRX Pharmaceuticals Reports Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At The European Society Of Emergency Medicine Meeting,2015-10-09 07:00:00-04:00,ACRX,negative
19607.0,AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso,2015-10-08 07:04:00-04:00,ACRX,neutral
19608.0,AcelRx Pharma Offers Regulatory Update on Zalviso: Minutes from FDA's DAAAP Meeting Showed Restated Request for Clinical Data to Complement Other Data AcelRx Developed,2015-10-08 07:03:00-04:00,ACRX,neutral
19609.0,AcelRx Pharmaceuticals Announces Initiation of Clinical Study with ARX-04 in Emergency Room Patients with Moderate-to-Severe Acute Pain,2015-10-06 07:07:00-04:00,ACRX,negative
19610.0,AcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for Zalviso for Treatment of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients; Triggers $15M Payment Milestone,2015-09-22 08:42:00-04:00,ACRX,negative
19611.0,Morning Market Gainers,2015-09-21 09:42:00-04:00,ACRX,neutral
19612.0,Benzinga's Top #PreMarket Gainers,2015-09-21 08:15:00-04:00,ACRX,positive
19613.0,"PDL BioPharma Announces Acquisition of Portion of AcelRx Pharma, Royalties, Expected Milestones from Zalviso for $65M",2015-09-21 07:01:00-04:00,ACRX,neutral
19614.0,Morning Market Gainers,2015-09-09 09:39:00-04:00,ACRX,neutral
19615.0,Benzinga's Top #PreMarket Gainers,2015-09-09 08:09:00-04:00,ACRX,positive
19616.0,8-K from AcelRx Pharma Shows ARX-04 Has Met All Endpoints in PIVOTAL Phase 3 Study for Moderate-to-Severe Acute Pain,2015-09-09 06:14:00-04:00,ACRX,negative
19617.0,Morning Market Losers,2015-09-08 09:51:00-04:00,ACRX,negative
19618.0,Benzinga's Top #PreMarket Losers,2015-09-08 08:28:00-04:00,ACRX,negative
19619.0,3 Catalysts To Watch Over The Next Couple Months For This Pharma Co.,2015-09-02 11:18:00-04:00,ACRX,neutral
19620.0,Morning Market Gainers,2015-07-24 09:42:00-04:00,ACRX,neutral
19621.0,AcelRx Reports Positive CHMP Opinion for Zalviso for Acute Moderate to Sever Post-Operative Pain,2015-07-24 08:30:00-04:00,ACRX,positive
19622.0,AcelRx Pharmaceuticals Shares +15% Premarket; Hearing Positive EMA Reccomendation for Sufentanil,2015-07-24 08:04:00-04:00,ACRX,positive
19623.0,Option Alert: AcelRx Pharma Aug $5 Call; 1261 Contracts Traded vs 465 OI; Now $4.45,2015-07-23 15:57:00-04:00,ACRX,positive
19624.0,Zalviso Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain,2015-07-02 07:02:00-04:00,ACRX,negative
19625.0,7 Biotech Stocks Moving Off The UBS Healthcare Conference,2015-05-19 14:16:00-04:00,ACRX,neutral
19626.0,Morning Market Gainers,2015-05-14 09:44:00-04:00,ACRX,neutral
19627.0,Benzinga's Top #PreMarket Gainers,2015-05-14 08:10:00-04:00,ACRX,positive
19628.0,US Stock Futures Surge Ahead Of Jobless Claims,2015-05-14 07:14:00-04:00,ACRX,neutral
19629.0,AcelRx Awarded Up to $17M Contract from Department of Defense to Advance ARX-04,2015-05-14 07:04:00-04:00,ACRX,positive
19630.0,Stocks Hitting 52-Week Lows,2015-05-05 10:26:00-04:00,ACRX,negative
19631.0,Morning Market Losers,2015-05-05 09:57:00-04:00,ACRX,negative
19632.0,Benzinga's Top #PreMarket Losers,2015-05-05 08:21:00-04:00,ACRX,negative
19633.0,Bill Ackman Boosts Jarden; Nautilus Wins Big In After-Hours Trading,2015-05-04 19:06:00-04:00,ACRX,positive
19634.0,AcelRx Shares to Resume Trade at 4:30 p.m. EDT,2015-05-04 16:11:00-04:00,ACRX,positive
19635.0,"AcelRx Reports Q1 GAAP Loss of $0.27/Share, May Not Compare to $0.44/Share Gain Est.; Co. Says FDA Panel Restated View Clinical Study is Necessary, Request for Meeting was Denied",2015-05-04 16:06:00-04:00,ACRX,negative
19636.0,AcelRx Shares Halted News Pending,2015-05-04 16:00:00-04:00,ACRX,positive
19637.0,"Global Hunter Initiates Coverage on AcelRx Pharmaceuticals at Accumulate, Announces $22.00 PT",2015-04-27 09:13:00-04:00,ACRX,neutral
19638.0,Stocks Hitting 52-Week Lows,2015-03-30 10:50:00-04:00,ACRX,negative
19639.0,"8-K from AcelRx Pharma Shows Grunenthal Confirmed CHMP of EMA Received Responses, Says Expecting to Get EMA Day-180 List of Issues During Q2",2015-03-23 07:36:00-04:00,ACRX,neutral
19640.0,9 Management Changes From The Past Week,2015-03-20 17:04:00-04:00,ACRX,neutral
19641.0,"AcelRx Reports Restructure To Focus On Zalviso Approval; Cutting 19 Jobs, Will Incur $900K Chare For Cuts",2015-03-20 15:02:00-04:00,ACRX,positive
19642.0,AcelRx Names Howard Rosen Interim CEO,2015-03-20 15:00:00-04:00,ACRX,neutral
19643.0,AcelRx Pharma Reports Initiation of Pivotal Phase 3 Trial for ARX-04 for Treatment of Moderate-to-Severe Acute Pain,2015-03-16 07:04:00-04:00,ACRX,negative
19644.0,Jefferies Downgrades AcelRx Pharmaceuticals After FDA Requests Additional Clinical Trial For Lead Drug Zalviso,2015-03-10 11:55:00-04:00,ACRX,neutral
19645.0,"Cowen & Company Downgrades AcelRx Pharmaceuticals to Market Perform, Removes $14.00 PT",2015-03-10 10:45:00-04:00,ACRX,neutral
19646.0,Jefferies Downgrades AcelRx Pharmaceuticals To Hold,2015-03-10 09:29:00-04:00,ACRX,neutral
19647.0,Benzinga's Top Downgrades,2015-03-10 09:05:00-04:00,ACRX,positive
19648.0,"Jefferies Downgrades AcelRx Pharmaceuticals to Hold, Lowers PT to $6.00",2015-03-10 05:56:00-04:00,ACRX,negative
19649.0,"Mizuho Securities Downgrades AcelRx Pharmaceuticals to Neutral, Lowers PT to $5.59",2015-03-10 04:40:00-04:00,ACRX,positive
19650.0,"AcelRx Pharma Meets Expectations, But Says It Won't Submit New Zalviso Application",2015-03-09 22:10:00-04:00,ACRX,neutral
19651.0,"AcelRx Pharma Reports Q4 EPS -$0.32 Vs Est -$0.30, Sales $226K Vs Est $590.0K",2015-03-09 16:08:00-04:00,ACRX,neutral
19652.0,Mizuho Securities Downgrades AcelRx Pharmaceuticals to Neutral,2015-03-09 11:07:00-04:00,ACRX,positive
19653.0,Morning Market Losers,2015-03-09 09:54:00-04:00,ACRX,negative
19654.0,Benzinga's Top #PreMarket Losers,2015-03-09 08:17:00-04:00,ACRX,negative
19655.0,AcelRx Receives FDA Update Regarding NDA Application For Zalviso,2015-03-09 07:32:00-04:00,ACRX,neutral
19656.0,"Mizuho Securities Upgrades AcelRx Pharmaceuticals to Buy, Raises PT to $14.00",2015-02-26 04:56:00-05:00,ACRX,positive
19657.0,"AcelRx Pharmaceuticals Announces Departure of Richard A. King, President And CEO",2014-12-16 17:05:00-05:00,ACRX,neutral
19658.0,AcelRx Reports Receiving of CE Mark Approval for Zalviso,2014-12-02 07:01:00-05:00,ACRX,positive
19659.0,Mid-Afternoon Market Update: Vivint Solar Dips After Wider-Than-Expected Q3 Loss; Rackspace Shares Spike Higher,2014-11-11 15:17:00-05:00,ACRX,neutral
19660.0,Mid-Morning Market Update: Markets Edge Lower; D.R. Horton Posts Downbeat Profit,2014-11-11 10:35:00-05:00,ACRX,positive
19661.0,Shares of AcelRx Pharmaceuticals Rise 16%; May be Attributed to Positive Guggenheim Note,2014-11-11 10:02:00-05:00,ACRX,positive
19662.0,"AcelRx Pharmaceuticals, Inc. Reports Q3 EPS of $(0.13) vs $(0.22) Est",2014-11-10 16:24:00-05:00,ACRX,neutral
19663.0,AcelRx Pharmaceuticals Receives International Standards Organization Certification Of Its Quality Management System,2014-11-10 07:09:00-05:00,ACRX,neutral
19664.0,"Mizuho Securities Downgrades AcelRx Pharmaceuticals, Inc. to Neutral, Lowers PT to $6.00",2014-11-06 05:48:00-05:00,ACRX,positive
19665.0,Acelrx Pharmaceuticals Announces CEO Richard King To Leave Company ,2014-11-05 16:05:00-05:00,ACRX,negative
19666.0,AcelRx Pharmaceuticals Announces Sublingual Sufentanil Data Presentations At The American College Of Surgeons Meeting,2014-10-27 07:40:00-04:00,ACRX,neutral
19667.0,AcelRx Pharmaceuticals Announces Update on Patent Portfolio for Zalviso,2014-10-16 07:03:00-04:00,ACRX,neutral
19668.0,Nike Jumps On Strong Results; Powell Industries Shares Slide,2014-09-26 13:04:00-04:00,ACRX,positive
19669.0,"Roth Capital Downgrades AcelRx Pharmaceuticals, Inc. to Neutral, Lowers PT to $6.00",2014-09-26 12:45:00-04:00,ACRX,negative
19670.0,Stocks Hitting 52-Week Lows,2014-09-26 10:07:00-04:00,ACRX,negative
19671.0,Morning Market Losers ,2014-09-26 09:45:00-04:00,ACRX,negative
19672.0,"BlackBerry Ltd, AcelRx & Benzinga's Top PreMarket Losers",2014-09-26 08:08:00-04:00,ACRX,negative
19673.0,"AcelRx Pharma Offers Regulatory Update for Zalviso: Aiming for NDA Resubmission During Q1'15, But Could Be Later",2014-09-26 07:08:00-04:00,ACRX,neutral
19674.0,"AcelRx Pharmaceuticals, Inc. Reports Q2 EPS of $(0.30) Which May Not Compare $(0.26) Est; Revenue of $71.0K Which May Not Compare $40.0K Est",2014-08-11 16:07:00-04:00,ACRX,neutral
19675.0,"Piper Jaffray Downgrades AcelRx Pharmaceuticals, Inc. to Neutral, Lowers PT to $8.00",2014-07-29 06:53:00-04:00,ACRX,negative
19676.0,Morning Market Losers ,2014-07-28 09:48:00-04:00,ACRX,negative
19677.0,AcelRX Selling Off Sharply On FDA Reexamination,2014-07-28 09:15:00-04:00,ACRX,neutral
19678.0,Benzinga's Top Downgrades,2014-07-28 08:58:00-04:00,ACRX,positive
19679.0,Benzinga's Top #PreMarket Losers,2014-07-28 08:19:00-04:00,ACRX,negative
19680.0, Canaccord Genuity Downgrades AcelRx Pharmaceuticals To Hold,2014-07-28 07:33:00-04:00,ACRX,neutral
19681.0,"AcelRx Pharmaceuticals Resume Trading, Now Down 30% Premarket, Following Receipt of CRL from FDA for NDA for Zalviso",2014-07-28 07:11:00-04:00,ACRX,neutral
19682.0,PREVIEW: AcelRx Pharmaceuticals to Resume Trading at 7:00AM ET,2014-07-28 06:56:00-04:00,ACRX,neutral
19683.0,"Canaccord Genuity Downgrades AcelRx Pharmaceuticals, Inc. to Hold, Lowers PT to $8.00",2014-07-28 06:43:00-04:00,ACRX,negative
19684.0,AcelRx Pharmaceuticals Receives CRL from FDA for NDA for Zalviso,2014-07-25 22:24:00-04:00,ACRX,neutral
19685.0,Benzinga's Top #PreMarket Gainers,2014-07-25 08:13:00-04:00,ACRX,positive
19686.0,"AcelRx Pharmaceuticals Confirms PDUFA Date for Zalviso is July 27, 2014 ",2014-07-25 05:23:00-04:00,ACRX,neutral
19687.0,US Stock Futures Down In Pre-Market Trade,2014-07-07 07:34:00-04:00,ACRX,neutral
19688.0,"Grunenthal Submits European Marketing Authorization Application for ZALVISO, Triggers $5M Milestone Payment to AcelRx",2014-07-07 05:26:00-04:00,ACRX,neutral
19689.0,"Corporate Events for the Week of Jun. 2nd, 2014",2014-06-02 18:19:00-04:00,ACRX,neutral
19690.0,AcelRX Announces Chief Commercial Officer To Step Down,2014-06-02 16:14:00-04:00,ACRX,neutral
19691.0,Filing from Acelrx Pharma Shows Mixed Shelf for Up to $150M,2014-05-19 17:16:00-04:00,ACRX,neutral
19692.0,"AcelRx Pharmaceuticals, Inc. Reports Q1 EPS of $(0.22) vs $(0.23) Est",2014-05-08 16:06:00-04:00,ACRX,neutral
19693.0,"Canaccord Genuity Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy",2014-04-17 07:41:00-04:00,ACRX,neutral
19694.0,"Roth Capital Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy, Announces $22.00 PT",2014-04-14 09:07:00-04:00,ACRX,neutral
19695.0,"AcelRx Pharmaceuticals, Inc. Reports Q4 EPS of $(0.18) vs $(0.17) Est",2014-03-03 16:07:00-05:00,ACRX,neutral
19696.0,"RBC Capital Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Outperform, Announces $15.00 PT",2014-01-06 17:17:00-05:00,ACRX,neutral
19697.0,"McNicoll Lewis Vlak Maintains Buy on AcelRx Pharmaceuticals, Inc., Raises PT to $16.50",2013-12-17 06:49:00-05:00,ACRX,neutral
19698.0,Benzinga's Top #PreMarket Gainers,2013-12-16 08:16:00-05:00,ACRX,positive
19699.0,"AcelRx, Grunenthal Announce Collaboration for EU Commercialization of ZALVISO",2013-12-16 07:52:00-05:00,ACRX,neutral
19700.0,Benzinga's Top #PreMarket Gainers,2013-12-13 08:32:00-05:00,ACRX,positive
19701.0,AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data,2013-12-13 07:33:00-05:00,ACRX,neutral
19702.0,AcelRx Announces Zalviso NDA Accepted for Filing by FDA ,2013-12-02 07:34:00-05:00,ACRX,positive
19703.0,Seeking Alpha: 'AcelRx: Huge Potential With Limited Risk',2013-11-27 13:57:00-05:00,ACRX,negative
19704.0,"AcelRx Pharmaceuticals, Inc. Reports Q3 EPS of $(0.26) vs $(0.19) Est; Revenue of $548.0K vs $340.0K Est",2013-11-05 17:00:00-05:00,ACRX,neutral
19705.0,"AcelRx Pharma Issues NDA for Zalviso, Submission Required Payment of $1.95M to FDA",2013-09-30 07:35:00-04:00,ACRX,neutral
19706.0,UPDATE: Jefferies Raises PT on AcelRx Pharmaceuticals on Numerous Potential Catalysts Ahead,2013-08-13 08:41:00-04:00,ACRX,neutral
19707.0,"Jefferies Maintains Buy on AcelRx Pharmaceuticals, Inc., Raises PT to $14.00",2013-08-13 06:29:00-04:00,ACRX,neutral
19708.0,"AcelRx Pharmaceuticals, Inc. Reports Q2 EPS of $(0.22), Inline",2013-08-12 16:05:00-04:00,ACRX,neutral
19709.0,"Form 8-K: Acelrx Pharma, Mallinckrodt Announcing Supply Deal",2013-08-09 16:10:00-04:00,ACRX,neutral
19710.0,AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock At $11.65,2013-07-18 09:25:00-04:00,ACRX,neutral
19711.0,AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock,2013-07-17 16:02:00-04:00,ACRX,neutral
19712.0,Benzinga's Volume Movers,2013-07-02 10:28:00-04:00,ACRX,neutral
19713.0,Hearing Guggenheim Positive on Acelrx,2013-07-02 09:44:00-04:00,ACRX,positive
19714.0,AcelRx Pharmaceuticals Joins Russell Global and Russell 3000 Indexes ,2013-07-02 07:35:00-04:00,ACRX,neutral
19715.0,UPDATE: Jefferies Raises PT on AcelRx Pharmaceuticals Following Model Assumption Updates,2013-06-18 10:26:00-04:00,ACRX,neutral
19716.0,"Jefferies Maintains Buy on AcelRx Pharmaceuticals, Inc., Raises PT to $13.00",2013-06-18 07:54:00-04:00,ACRX,neutral
19717.0,Benzinga's Top Pre-Market Gainers,2013-05-21 08:10:00-04:00,ACRX,positive
19718.0,"AcelRx Pharmaceuticals, Inc. Reports Q1 EPS of $(0.34) vs $(0.27) Est; Revenue of $940.0K vs $830.0K Est",2013-05-08 17:07:00-04:00,ACRX,neutral
19719.0,AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting,2013-05-02 07:31:00-04:00,ACRX,positive
19720.0,Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial,2013-04-24 07:30:00-04:00,ACRX,neutral
19721.0,UPDATE: Jefferies Initiates AcelRx Pharmaceuticals with Buy on Expected FDA Approval for ARX-01,2013-04-08 09:43:00-04:00,ACRX,positive
19722.0,Benzinga's Top Initiations,2013-04-08 09:01:00-04:00,ACRX,positive
19723.0,"Jefferies Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy, Announces $8.00 PT",2013-04-08 08:25:00-04:00,ACRX,neutral
19724.0,"Jefferies Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy, Announces $8.00 PT",2013-04-08 06:19:00-04:00,ACRX,neutral
19725.0,Acelrx Pharmceuticals Moves Higher; May be Attributed to Error in Press Release Regarding Available Cash,2013-03-15 10:41:00-04:00,ACRX,negative
19726.0,AcelRx Pharma Offers Updates on Clinical Trials,2013-02-19 07:40:00-05:00,ACRX,neutral
19727.0,"McNicoll Lewis Vlak  Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy, Announces $13.00 undefined",2013-02-04 12:47:00-05:00,ACRX,neutral
19728.0,"Mizuho Securities Initiates Coverage on AcelRx Pharmaceuticals, Inc. at Buy, Announces $13.00 PT",2013-01-29 16:41:00-05:00,ACRX,positive
19729.0,ACP IV L.P. Files 13D Showing 7.5% Stake in Acelrx Pharma,2012-12-18 13:56:00-05:00,ACRX,neutral
19730.0,AcelRx Pharma Announces Exercise of Option to Buy Additional Shares,2012-12-14 12:16:00-05:00,ACRX,positive
19731.0,Perceptive Advisor Showing 14.25% Stake in Acelrx Pharma ,2012-12-13 15:16:00-05:00,ACRX,neutral
19732.0,Acelrx Spikes Higher,2012-12-11 15:17:00-05:00,ACRX,neutral
19733.0,Benzinga's Top Pre-Market Gainers,2012-12-07 08:10:00-05:00,ACRX,positive
19734.0,AcelRx Pharmaceuticals Prices 12.5M Share Offering at $3.31/Share,2012-12-07 06:33:00-05:00,ACRX,positive
19735.0,A Peek Into The Market Before The Trading Starts,2012-12-05 07:09:00-05:00,ACRX,neutral
19736.0,AcelRx Pharmaceuticals Announces Proposed 10M Share Secondary Offering,2012-12-05 06:18:00-05:00,ACRX,positive
19737.0,FROM EARLIER: AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab® PCA System vs. IV PCA Morphine for Post-Operative Pain,2012-11-15 08:28:00-05:00,ACRX,negative
19738.0,AcelRx Announces Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System Meets Primary End-Point ,2012-11-14 22:24:00-05:00,ACRX,neutral
19739.0,Acelrx Pharmaceuticals Reports Q3 EPS $-0.38 vs $-0.38 Est; Revenues $166K vs $320.00K Est,2012-11-06 16:28:00-05:00,ACRX,neutral
19740.0,AcelRx Pharmaceuticals Doses the First Subjects in ARX-04 Phase 2 Study,2012-11-05 07:39:00-05:00,ACRX,neutral
19741.0,AcelRx Receives Notice of Eligibility for Centralized Review from European Medicines Agency for the Sufentanil NanoTab PCA System ,2012-10-03 07:41:00-04:00,ACRX,neutral
19742.0,AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms ,2012-08-29 07:32:00-04:00,ACRX,neutral
19743.0,AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms ,2012-08-01 07:34:00-04:00,ACRX,neutral
19744.0,AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms ,2012-06-20 07:30:00-04:00,ACRX,neutral
19745.0,AcelRx Pharmaceuticals Announces Pricing of a $10.0M PIPE Financing ,2012-05-30 07:31:00-04:00,ACRX,neutral
19746.0,"AcelRx Announces Initiation of Second Phase 3 Clinical Trial for ARX-01, the Sufentanil NanoTab PCA System, for the Treatment of Acute Post-Operative Pain ",2012-04-12 07:30:00-04:00,ACRX,negative
19747.0,"Benzinga's Microcap Movers for Wednesday March 7, 2012",2012-03-08 07:29:00-05:00,ACRX,neutral
19748.0,"AcelRx Announces Initiation of Phase 3 Clinical Program for ARX-01, the Sufentanil NanoTab® PCA System for the Treatment of Post-Operative Pain",2012-03-07 07:23:00-05:00,ACRX,negative
19749.0,AcelRx Announces its ARX-01 Phase 3 Program Expected to Start Late Q1 or Early Q2 2012 ,2012-01-31 07:31:00-05:00,ACRX,neutral
19750.0,Morning Market Losers ,2011-12-30 10:24:00-05:00,ACRX,negative
19751.0,AcelRx Pharmaceuticals Appoints Mark G. Edwards To Its Board of Directors ,2011-09-28 07:31:00-04:00,ACRX,neutral
19752.0,"AcelRx Secures $20 Million Loan Financing Agreement, Expected to Extend Its Operating Cash Runway Into 2013",2011-06-30 13:31:00-04:00,ACRX,positive
19753.0,AcelRx Announces $5.6 Million Department of Defense Grant to Develop ARX-04,2011-05-31 07:32:00-04:00,ACRX,positive
19754.0,AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period ,2011-05-10 07:41:00-04:00,ACRX,negative
19755.0,Piper Jaffray Overweight On AcelRx Pharmaceuticals  (ACRX),2011-04-01 07:54:00-04:00,ACRX,negative
19756.0,"Piper Jaffray Initiates AcelRx Pharmaceuticals At Overweight, $7 PT",2011-03-24 07:45:00-04:00,ACRX,negative
